Data / Form D filings / RAVGEN, INC.
RAVGEN, INC.: Form D filings
RAVGEN, INC., a biotechnology company in Columbia, MD, filed 7 Form D notices with the SEC between 2011 and 2021. The latest, on October 27, 2021, reports $2.5 million sold of a $3.5 million offering to 11 investors.
Find out what RAVGEN, INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9241 RUMSEY ROAD, Columbia, MD, 21045
- Phone
- (410) 715-2111
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1140834
The full lists. Form D filings in Maryland: 608 rows, $30.40, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 27, 2021 | Amendment | $3,500,000 | $2,481,652 | $1,018,348 | 11 | May 20, 2021 | sec.gov |
| Aug 9, 2021 | Amendment | $3,500,000 | $2,450,000 | $1,050,000 | 8 | May 20, 2021 | sec.gov |
| Jul 27, 2021 | Amendment | $3,500,000 | $2,150,000 | $1,350,000 | 6 | May 20, 2021 | sec.gov |
| Jul 2, 2021 | Amendment | $3,500,000 | $1,900,000 | $1,600,000 | 5 | May 20, 2021 | sec.gov |
| Jun 3, 2021 | New notice | $3,500,000 | $800,000 | $2,700,000 | 3 | May 20, 2021 | sec.gov |
| May 14, 2012 | Amendment | Indefinite | $1,091,663 | Indefinite | 15 | Apr 1, 2010 | sec.gov |
| May 13, 2011 | New notice | Indefinite | $884,400 | Indefinite | 11 | Apr 1, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kamlesh Dhallan | Director | |
| Philip Bayliss | Director | |
| Edward Mottern | Director | |
| Narender Dhallan | Director | |
| Ravinder Dhallan | Executive Officer, Director, Promoter |
Other biotechnology companies in Maryland that filed recently
- BlueHealer Inc. $1 · Nov 4, 2026
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
- Uvantis Therapeutics, Inc. $100,000 · Sep 23, 2026
- Gliknik Inc $15 million · Sep 17, 2026
- Georgiamune, Inc. $92.7 million · Aug 17, 2026
Every Form D from the week of Oct 25, 2021 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what RAVGEN, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.